Table of Contents
Shanghai Zerun Biotechnology
Shanghai Zerun Biotechnology Co. Ltd. is a Chinese biotechnology company based in Shanghai, China. It operates as a subsidiary of Walvax Biotechnology.
Activities
Research and development
The company has received three grants from the Bill & Melinda Gates Foundation.
- September 2015: $5,003,336 to improve women's access to low-cost bivalent HPV vaccine in GAVI-supported countries1)
- October 2019: $2,505,923 to improve women's access to low-cost nonavalent HPV vaccine in GAVI-supported countries2)
In July 2021, the Coalition for Epidemic Preparedness Innovations (CEPI) announced that it had partnered with Shanghai Zerun Biotechnology and its parent company, Walvax Biotech, to develop COVID-19 vaccine candidates against both the original strain of SARS-CoV-2 and its newer variants.4) As of October 2022, CEPI had provided up to $25.1 million USD towards a candidate called 202-CoV, but had ceased further funding.5) The chimeric protein candidate remains in Phase I clinical trials.
External links
1)
Shanghai Zerun Biotechnology Co., Ltd. (2015, September). Bill & Melinda Gates Foundation. https://web.archive.org/web/20221101031710/https://www.gatesfoundation.org/about/committed-grants/2015/09/opp1127764
2)
Shanghai Zerun Biotechnology Co., Ltd. (2019, October). Bill & Melinda Gates Foundation. https://web.archive.org/web/20221101031958/https://www.gatesfoundation.org/about/committed-grants/2019/10/opp1210446
3)
Shanghai Zerun Biotechnology Co., Ltd. (2020, May). Bill & Melinda Gates Foundation. https://archive.ph/yNHyg
4)
CEPI partners with Shanghai Zerun Biotech to develop COVID-19 variant vaccine. (2021, July 21). CEPI. https://web.archive.org/web/20220611060746/https://cepi.net/news_cepi/cepi-partners-with-shanghai-zerun-biotech-to-develop-covid-19-variant-vaccine/
5)
Who we are. CEPI. Retrieved October 19, 2022, from https://web.archive.org/web/20221019165747/https://cepi.net/about/whoweare/